Marine biotechnology

Engineered luciferases and fluorescent proteins derived from jellyfish, deep-sea shrimp and other marine organisms, redesigned via directed evolution and computational protein design into ultra-bright, photostable research tools for drug screening, cell imaging and protein-protein interaction detection.

Marine-derived ingredients and biomaterials — microalgal DHA/EPA omega-3, microalgae protein, seaweed biostimulants and bioplastics — cultivated from marine micro- and macroalgae to replace fish-oil and petrochemical supply chains serving infant formula, nutrition, feed and materials.

The UN High Seas Treaty (BBNJ Agreement) entered into force in January 2026, creating the first legal regime for accessing and sharing benefits from marine genetic resources collected outside any nation's waters — turning deep-sea genomic prospecting from an unregulated commons into a treaty-governed pipeline running from Ocean Genome Legacy's biobank to PharmaMar's marine-derived oncology drugs.